Gene expression changes in tumor following ADH-503 treatment

To understand the effect of ADH-503, we have employed microarray expression profiling to identify genes that change at different times 48hrs and 10 days after treatment initiation. CD11b/18 (alphaMbeta2), an integrin molecule is highly expressed on all myeloid cells and plays an important role in transendothelial migration and functional changes in these cells. Here we demonstrate that a small molecule agonist of CD11b, ADH-503 was associated reprograming tumor immunity by promoting anti-tumor immune cell populations by enhancing antigen presentation by macrophages and cDCs and together these changes resulted in stabilization of tumor growth and improvement in overall survival. To understand the effect of ADH-503, we have employed microarray expression profiling to identify genes that change at different times after treatment initiation. Treatment induced changes in gene expression at 48hrs and 10days after therapy in orthotopic pancreatic cancer model.